Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Almacid
- Development stage
- Unknown
- Lead developer
- Garima Health Care
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Almacid is an oral suspension antacid and antiflatulent combination developed by Garima Health Care. It contains dried aluminium hydroxide, magnesium hydroxide, and simethicone. Aluminium hydroxide and magnesium hydroxide are antacids that work by chemically neutralizing gastric hydrochloric acid, thereby raising the stomach pH and relieving symptoms of acidity, heartburn, and indigestion. Simethicone is an anti-foaming agent that reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and easier expulsion to relieve bloating and flatulence. Almacid is approved in India for the treatment of acidity, heartburn, indigestion, bloating, and stomach ulcers.
- Brand names
- Almacid
- Other names
- Almacid Oral Suspensionaluminium hydroxide + magnesium hydroxide + simethicone
Beyond the preview
Go deeper on Almacid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Almacid.